Key Takeaways
- Volume-led recovery takes hold: Revenue grew 5% QoQ and PAT 20% QoQ, driven by a 12% QoQ volume jump from recently commissioned capacities, even as realizations fell across all products.
- Derivatives & Specialty mix hits 46%: The revenue share from this segment nearly doubled from 29% a year ago, reflecting new capacity commissioning and improving utilization, a structural shift that reduces dependence on the commodity Chlor-Alkali cycle.
- EBITDA margin guided to 24–25%: Margins improved to 23% in Q2 from 21% in Q1 on higher utilization, and management expects the full-year range to be 24–25%, with H2 definitively better than H1.
- FY27 revenue target carries a caveat: The INR 5,000 crore aspirational goal is achievable if things move per plan, but management explicitly flagged it could be lower if the FY24 demand situation persists.
- What to watch next quarter: The pace of Epichlorohydrin export volume ramp-up from the Antwerp and Houston tank infrastructure, and whether CPVC realizations stabilize after the recent PVC-linked decline.
Volume & Revenue Recovery
- New capacities driving the bus: Volume growth of 21% YoY and 12% QoQ came from projects commissioned last year: CPVC Resin, Epichlorohydrin, and additional Caustic Soda capacity, with Derivatives & Specialty contributing the larger share.
- Sequential improvement from September: Q2 was better than Q1 on all parameters, with a noticeable improvement witnessed from September onwards, and management expects this trajectory to continue.
- Destocking drag easing: Destocking is still continuing but things have improved compared to Q1, and a slight improvement in Caustic Soda demand is expected as this headwind fades and export-oriented companies resume shipments.
- H2 to outpace H1: Management stated H2 will be definitely better than H1, with Q3 and Q4 improving on every quarter, supported by the CPVC peak season in Q2 and Q3 and improving Epichlorohydrin utilization.
Maulik Patel: "We witnessed an improvement from September month onwards and from current business scenario. We believe that the coming quarters would be better than Q2."
Derivatives & Specialty: The Mix Shift
- Structural transformation underway: Derivatives & Specialty revenue share rose to 46% in Q2 FY24 from 29% in Q2 FY23 and 37% in Q1 FY24, driven by new capacity commissioning and improving utilization rates.
- Epichlorohydrin export engine starting: Infrastructure is in place with tank hiring at Antwerp and Houston; products have reached Europe and the US, been approved and tried by customers, with volume pick-up beginning in Q2 and expected to improve from Q3 onward.
- CPVC expansion on track: Capacity expansion from 30,000 to 45,000 tons will be completed in Q4, and a new 35,000-ton CPVC Compound plant is under construction with commissioning targeted for end of Q4.
- Captive chlorine integration deepens: Current captive chlorine consumption plus pipeline customers stands at around 70%; as CPVC expansion continues and the Chlorotoluene plant commissions, this can reach up to 80% at full Caustic Soda capacity, insulating margins from merchant chlorine volatility.
CPVC: Demand & Competitive Position
- Scale leadership cemented: Epigral is currently the largest manufacturer of CPVC Resin in India and, after the Q4 expansion, will be the third or fourth largest in the world at a single location.
- Demand drivers multiplying: Infrastructure projects in Tier 2 and Tier 3 cities, builders adopting CPVC pipe even for cold water applications, and the potential fire sprinkler application, not yet approved in India but pursued by all manufacturers, are all expected to drive demand growth.
- Pricing linked to PVC: CPVC price has reduced a little because PVC has also declined over the last two to three months, as PVC is a major driver for CPVC costing.
- Competitor capacity years away: Any new large capacity, such as Lubrizol's, will take two to three years to commission, by which time the Indian market, currently around 250,000 tons, could exceed 300,000 to 350,000 tons.
- No demand-supply mismatch feared: Current demand for CPVC hot application pipe alone is large enough for any supplier to meet, and the growth story is expected to continue.
Maulik Patel: "if it is approved in the fire application, then it will be the huge, huge, huge, application for the Indian market for the infrastructure"
Margins & Profitability
- Utilization leverage visible: EBITDA margin improved to 23% in Q2 FY24 from 21% in Q1 FY24, backed by higher capacity utilization and higher volume, despite a fall in sales realization across all products.
- Full-year margin guided: Management expects EBITDA margin this year in the range of 24% to 25%, achievable considering the current situation.
- Realization seen near bottom: Management believes current realization is a kind of bottom-out and things have to go up from here, though the exact timing, whether November, December, or later, is uncertain.
- Product-level margin consistent: When asked about CPVC versus PVC spreads, management declined to share product-to-product details but stated margins would be in line with the company as a whole at around 25%.
Balance Sheet & Capital Allocation
- Debt range steady: Debt is expected to remain in the range of INR 970–980 crore after the Chlorotoluene and CPVC expansion, with debt repayment on a yearly basis offsetting new debt.
- Preferential payment on schedule: INR 61 crore was paid last year to Meghmani Organics, with INR 150 crore remaining to be paid over four years as per the committed schedule.
- No shareholder return action planned: When asked about a buyback or bonus issue, management stated that as of now, there is nothing on the table.
- Sales guidance withheld: Management declined to provide sales guidance for this year or next year.
Long-Term Growth Framework
- Volume growth engine via CapEx: Volume growth is expected at 15–20% every year through CapEx, with ECH and Caustic Soda not yet at optimum capacity driving growth in FY24, and additional CPVC and Chlorotoluene capacity driving growth in FY25.
- FY27 target is aspirational, not assured: The INR 5,000 crore revenue target is achievable if things move per plan, but management explicitly acknowledged it could be lower if the situation remains like FY24.
- Consistent growth ambition: The company is targeting consistent growth at both top line and bottom line through future expansion and diversification, with the long-term India story intact despite near-term headwinds.
Milind Kotecha: "INR 5,000 crore is something that we have keep a target to achieve and that's where we are targeting in terms of the CapEx and the volumes... If things move as per our plan, then INR 5,000 crore can be achieved and if the situation is like FY24, which is there right now, then these can be bit lower than what we have given."
Kaushal Soparkar: "the long-term story of India is intact and current situation is short term"
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| H2 outperformance | H2 will be definitely better than H1; Q3 and Q4 will improve on every quarter | FY24 H2 |
| EBITDA margin | Full-year EBITDA margin in the range of 24% to 25% | FY24 |
| CPVC capacity expansion | Expansion from 30,000 to 45,000 tons completed | Q4 FY24 |
| CPVC Compound plant | 35,000-ton plant commissioned | End of Q4 FY24 |
| Epichlorohydrin utilization | Capacity utilization to further improve | Q3 FY24 onward |
| Debt level | Remain in range of INR 970–980 crore after Chlorotoluene and CPVC expansion | Near term |
| Meghmani Organics payment | INR 150 crore remaining paid over four years | Over four years |
| Captive chlorine consumption | Reach up to 80% at full Caustic Soda capacity | When CPVC expansion and Chlorotoluene plant commission |
| FY27 revenue target | INR 5,000 crore aspirational; lower if FY24-like situation persists | FY27 |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue | ₹479 cr, +5% QoQ, -40% YoY |
| EBITDA | ₹108 cr, +13% QoQ, -40% YoY |
| EBITDA margin | 23%, vs 21% in Q1 FY24 |
| PAT | ₹38 cr, +20% QoQ, -58% YoY |
| Revenue from Derivatives & Specialty | 46% of total revenue, vs 29% in Q2 FY23 and 37% in Q1 FY24 |
| Volume growth | +12% QoQ, +21% YoY; Derivatives & Specialty +37%, Chlor-Alkali +13% |
| Overall plant capacity utilization | 77%, vs 71% in Q1 FY24 |
| CPVC capacity utilization | 80–85% |
| Epichlorohydrin capacity utilization | 45–50% |
| Caustic Soda capacity utilization | 75–78% |
| ECU (Chlor-Alkali) | ₹29,000–30,000, vs ₹28,000–29,000 in Q1 FY24 |
| Captive chlorine consumption | ~70% |
| Net debt | ₹961 cr as on 30 Sep 2023, vs ₹863 cr as on 31 Mar 2023 |
| Net debt to EBITDA | 1.8x, vs 1.3x in Q2 FY23 |
| Net debt to equity | 0.9x in Q1 FY24, vs 1x in Q2 FY23 |
| ROC (trailing 12 months) | 21% including CWIP, 23% excluding CWIP |
| Capex spent in Q2 FY24 | ₹117 cr |
| Cost of borrowing | 8.25% |
| CPVC price | ₹135–140 per kg level |
| EBITDA margin guidance for FY24 | 24–25% (per management) |